Expanded access to phase II clinical trials in oncology: A step toward increasing scientific validity and compassion

被引：0
作者：
Marcee, Alice K. [1 ]
机构：
[1] So Methodist Univ, Dedman Sch Law, Dallas, TX 75275 USA
来源：
FOOD AND DRUG LAW JOURNAL | 2008年 / 63卷 / 02期
关键词：
D O I：
暂无
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
引用
收藏
页码：439 / 457
页数：19
相关论文
共 50 条
[31]   An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials [J].
Su, Zheng .
CLINICAL DRUG INVESTIGATION, 2010, 30 (06) :397-403
[32]   Predicting low accrual in the Clinical Trials Cooperative Group Program's phase II/III oncology trials [J].
Bennette, Caroline Savage ;
Ramsey, Scott David ;
McDermott, Cara L. ;
Carlson, Josh John ;
Basu, Anirban ;
Veenstra, David L. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[33]   Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years [J].
Barata, Pedro ;
Hobbs, Brian ;
Rini, Brian ;
Paller, Channing ;
Normolle, Dan ;
Garrett-Mayer, Elizabeth ;
Rubin, Eric ;
Rosner, Gary ;
Pond, Greg ;
Perlmutter, Jane ;
Seymour, Lesley ;
Siu, Lillian ;
Wages, Nolan ;
Ivy, Percy ;
Prowell, Tatiana ;
Yap, Timothy ;
Hong, David .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[34]   REPORTING OF RACIAL/ETHNIC MINORITY REPRESENTATION IN PHASE I/II PEDIATRIC ONCOLOGY CLINICAL TRIALS [J].
Faruqi, Aiman ;
Ligon, John ;
Cohen, Julia ;
Akshintala, Srivandana ;
Widemann, Brigitte ;
Shah, Nirali .
PEDIATRIC BLOOD & CANCER, 2022, 69 :S520-S520
[35]   Optimal, minimax and admissible two-stage design for phase II oncology clinical trials [J].
Fei Qin ;
Jingwei Wu ;
Feng Chen ;
Yongyue Wei ;
Yang Zhao ;
Zhiwei Jiang ;
Jianling Bai ;
Hao Yu .
BMC Medical Research Methodology, 20
[36]   Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials [J].
Berry, Scott M. ;
Broglio, Kristine R. ;
Groshen, Susan ;
Berry, Donald A. .
CLINICAL TRIALS, 2013, 10 (05) :720-734
[37]   Optimal, minimax and admissible two-stage design for phase II oncology clinical trials [J].
Qin, Fei ;
Wu, Jingwei ;
Chen, Feng ;
Wei, Yongyue ;
Zhao, Yang ;
Jiang, Zhiwei ;
Bai, Jianling ;
Yu, Hao .
BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
[38]   Validity of brain MRI as the primary outcome criterion in multiple sclerosis phase II clinical trials [J].
Liedtke, W ;
Limmroth, V .
ANNALS OF NEUROLOGY, 1996, 39 (02) :276-276
[39]   HEMATOPOIETIC GROWTH-FACTORS AND CHEMOPROTECTANTS - SHOULD WE MOVE TOWARD A 2-STEP PROCESS FOR PHASE-I CLINICAL-TRIALS IN ONCOLOGY [J].
MERROUCHE, Y ;
CATIMEL, G ;
CLAVEL, M .
ANNALS OF ONCOLOGY, 1993, 4 (06) :471-474
[40]   Access to Children's Oncology Group phase I clinical trials: Racial/ethnic dissimilarities in participation. [J].
Nooks, Ajay K. ;
Behera, Madhusmita ;
Lonial, Sager ;
Dixon, Margie ;
Georglevska, Biljana ;
Ramallngam, Suresh S. ;
Pentz, Rebecca D. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345